You are here
Report: Market for Pancreatic Cancer Therapies Expected to Double to $1.3 Billion Over Next Decade
Decision Resources, a research and advisory firm located in Burlington, Mass., finds that the pancreatic cancer therapy market will nearly double to $1.3 billion in 2022, owing to the launch and rapid uptake of three high-priced agents — Abraxane (paclitaxel, Celgene/Taiho); Estybon (rigosertib, Onconova Therapeutics/Baxter International/SymBio Pharmaceuticals); and MM-398 (Merrimack Pharmaceuticals), a novel formulation of irinotecan. Even though these agents do not substantially improve the overall survival of pancreatic cancer patients, they will have a significant effect on current treatment, the company says.
The report also finds that a significant commercial reward awaits developers of therapies that are more effective and better tolerated than the FOLFIRINOX regimen (folic acid [leucovorin calcium], fluorouracil, irinotecan hydrochloride, and oxaliplatin) in this disease, as the need for efficacious, well-tolerated therapies will remain through 2022.
“There is a dire need for novel therapies to, at a minimum, match FOLFIRINOX’s efficacy,” said analyst Orestis Mavroudis-Chocholis, PhD. “FOLFIRINOX is reserved for young, fitter patients, who are better able to tolerate it, and is therefore prescribed only to a minority of pancreatic cancer patients who typically have rapidly progressing disease and declining performance status. Even an agent with equal efficacy but a better safety profile will quickly become the standard of care in pancreatic cancer.”
The report also finds that surveyed physicians are excited by the prospect of stromal over-expression of secreted protein rich in cysteine (SPARC) as a predictive biomarker for a response to Abraxane and hope that this could herald the start of a personalized approach to the treatment of pancreatic cancer.
Source: Decision Resources; May 7, 2013.